• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    7/31/25 7:18:36 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    bax-20250731
    0000010456false00000104562025-07-312025-07-310000010456exch:XCHIbax:CommonStock1.00PerValueMember2025-07-312025-07-310000010456exch:XNYSbax:CommonStock1.00PerValueMember2025-07-312025-07-310000010456exch:XNYSbax:GlobalNotes13Due2029Member2025-07-312025-07-31

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): July 31, 2025
    Baxter International Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of incorporation)
    1-444836-0781620
    (Commission File Number)(I.R.S. Employer Identification No.)
    One Baxter Parkway, Deerfield, Illinois
    60015
    (Address of principal executive offices)(Zip Code)
    (224)948-2000
    (Registrant’s telephone number, including area code)
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange
    1.3% Global Notes due 2029BAX 29New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
    ☐ Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:   ☐



    Item 2.02 Results of Operations and Financial Condition.
    On July 31, 2025, Baxter International Inc. (the Company) issued an earnings press release for the period ended June 30, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report.

    The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits.
    Exhibit NumberDescription
    99.1
    Press Release Dated July 31, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: July 31, 2025
    BAXTER INTERNATIONAL INC.
    By:/s/ Joel T. Grade
    Name:Joel T. Grade
    Title:Executive Vice President and
    Chief Financial Officer


    Get the next $BAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    5/10/2024$40.00Buy → Hold
    TD Cowen
    More analyst ratings

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and General Counsel Rosenbloom David S. covered exercise/tax liability with 16,548 shares, decreasing direct ownership by 13% to 106,327 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/4/25 4:06:25 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Director Wilkes David S. was granted 7,183 shares, increasing direct ownership by 43% to 23,906 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    5/8/25 4:29:28 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Director Wendell Amy Mcbride was granted 7,183 shares, increasing direct ownership by 30% to 31,222 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    5/8/25 4:28:59 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Reports Second-Quarter 2025 Results

    Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

    7/31/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is g

    7/17/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on October 1, 2025, to stockholders of record as of August 29, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched po

    7/14/25 4:40:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Reports Second-Quarter 2025 Results

    Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

    7/31/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is g

    7/17/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on October 1, 2025, to stockholders of record as of August 29, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched po

    7/14/25 4:40:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Baxter with a new price target

    Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00

    2/26/25 7:01:30 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    SEC Form 10-Q filed by Baxter International Inc.

    10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    8/5/25 4:48:23 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    7/31/25 7:18:36 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    7/7/25 8:51:26 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care